Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label
6 hours ago
- #glycaemic control
- #type 1 diabetes
- #automated insulin delivery
- Tubeless automated insulin delivery (AID) systems were compared with multiple daily injections (MDI) in a randomized controlled trial (RADIANT) involving children and adults with type 1 diabetes and elevated HbA1c levels.
- The study included 188 participants aged 4-70 years, randomized 2:1 to either tubeless AID or MDI, with primary outcomes measured at 13 weeks.
- Results showed a significant reduction in HbA1c levels in the AID group (from 8.1% to 7.2%) compared to the MDI group (from 8.1% to 8.0%), with an adjusted mean difference of -0.8%.
- No severe hypoglycaemia or diabetic ketoacidosis episodes occurred in either group during the trial, though 39 adverse events were reported in the AID group versus 3 in the MDI group.
- The study concluded that tubeless AID is a safe and effective therapeutic option for improving glycaemic control in people with type 1 diabetes transitioning from MDI.